文献速递胸部肿瘤放疗

III期非小细胞肺癌患者放化疗期间及之后淋巴细胞动态与剂量及接受维持免疫治疗患者结局的相关性

Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy.
PubMed 文献 · Radiother Oncol · 2022-01-13

这项回顾性研究纳入66例接受根治性同步放化疗的III期非小细胞肺癌患者,分析淋巴细胞减少与恢复的动态及其与剂量和预后的关系。多数患者(65例)在同步放化疗期间出现淋巴细胞减少,39例(59.0%)为3级及以上;59例(89.3%)在同步放化疗后3个月恢复,7例(10.6%)持续存在淋巴细胞减少。多因素Cox回归显示淋巴细胞恢复与无进展生存期(HR 0.35,95%CI 0.13-0.93,p=0.034)和总生存期(HR 0.24,95%CI 0.08-0.68,p=0.007)显著相关;基于体素分析显示上纵隔剂量与同步放化疗结束时淋巴细胞减少强相关,但与3个月时无关。

要点

  • 59例(89.3%)在同步放化疗后3个月恢复,7例(10.6%)持续存在淋巴细胞减少。
  • 淋巴细胞恢复与无进展生存期(HR 0.35,95%CI 0.13-0.93,p=0.034)和总生存期(HR 0.24,95%CI 0.08-0.68,p=0.007)显著相关。

核心结论

  • 淋巴细胞恢复与接受同步放化疗及辅助免疫治疗患者的生存改善强相关,并与同步放化疗前后的淋巴细胞计数相关。
  • 基于体素分析显示大血管剂量与同步放化疗结束时淋巴细胞减少高度相关。
  • 因此,不仅应努力预防同步放化疗期间的淋巴细胞耗竭,还应帮助同步放化疗后的淋巴细胞恢复。

研究设计与样本

  • 回顾性研究,纳入66例接受根治性同步放化疗的III期非小细胞肺癌患者。
  • 在同步放化疗前、期间和之后获取绝对淋巴细胞计数(ALC)。
  • 持续淋巴细胞减少定义为同步放化疗后3个月时ALC < 500/μL。
  • 采用基于体素分析(VBA)研究区域剂量对淋巴细胞耗竭和恢复的影响。

主要发现

  • 大多数患者(65例)在同步放化疗期间出现淋巴细胞减少,其中39例(59.0%)为3级及以上淋巴细胞减少。
  • 59例(89.3%)在同步放化疗后3个月从治疗相关淋巴细胞减少中恢复,7例(10.6%)表现为持续淋巴细胞减少。
  • 与持续淋巴细胞减少相关的患者特征为年龄较大以及治疗前和治疗期间的ALC。
  • 多因素Cox回归分析中,淋巴细胞恢复被确定为无进展生存期(HR 0.35,95%CI 0.13-0.93,p=0.034)和总生存期(HR 0.24,95%CI 0.08-0.68,p=0.007)的显著预后因素。
  • 基于体素分析显示上纵隔剂量与同步放化疗结束时淋巴细胞减少强相关,但与同步放化疗后3个月时无关。

关键数值与推荐

  • 持续淋巴细胞减少定义为同步放化疗后3个月时ALC < 500/μL。
  • 3级及以上淋巴细胞减少:39例(59.0%)。
  • 同步放化疗后3个月淋巴细胞恢复:59例(89.3%);持续淋巴细胞减少:7例(10.6%)。
  • 无进展生存期:HR 0.35,95%CI 0.13-0.93,p=0.034。
  • 总生存期:HR 0.24,95%CI 0.08-0.68,p=0.007。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We investigated the dynamics of lymphocyte depletion and recovery during and after definitive concurrent chemoradiotherapy (CCRT), dose to which structures is correlated to them, and how they affect the prognosis of stage III non-small cell lung cancer (NSCLC) patients undergoing maintenance immunotherapy. METHODS AND MATERIALS: In this retrospective study, absolute lymphocyte counts (ALC) of 66 patients were obtained before, during, and after CCRT. Persistent lymphopenia was defined as ALC < 500/μL at 3 months after CCRT. The impact of regional dose on lymphocyte depletion and recovery was investigated using voxel-based analysis (VBA). RESULTS: Most patients (n = 65) experienced lymphopenia during CCRT: 39 patients (59.0%) had grade (G) 3+ lymphopenia. Fifty-nine patients (89.3%) recovered from treatment-related lymphopenia at 3 months after CCRT, whereas 7 (10.6%) showed persistent lymphopenia. Patient characteristics associated with persistent lymphopenia were older age and ALC before and during treatment. In multivariable Cox regression analysis, recovery from lymphopenia was identified as a significant prognostic factor for Progression Free Survival (HR 0.35, 95% CI 0.13-0.93, p = 0.034) and Overall Survival (HR 0.24, 95% CI 0.08-0.68, p = 0.007). Voxel-based analysis showed strong correlation of dose to the upper mediastinum with lymphopenia at the end of CCRT, but not at 3 months after CCRT. CONCLUSION: Recovery from lymphopenia is strongly correlated to improved survival of patients undergoing CCRT and adjuvant immunotherapy, and is correlated to lymphocyte counts pre- and post-CCRT. VBA reveals high correlation of dose to large vessels to lymphopenia at the end of CCRT. Therefore, efforts should be made not only for preventing lymphocyte depletion during CCRT but also for helping lymphocyte recovery after CCRT.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Cho Y, Kim Y, Chamseddine I, et al. Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy. Radiother Oncol. 2022. PMID: 35033601. doi:10.1016/j.radonc.2022.01.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。